Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland.
Ocular surface disease
active compounds
dry eye sensation
glaucoma medication
multicenter study
preservative
Journal
European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772
Informations de publication
Date de publication:
13 Dec 2022
13 Dec 2022
Historique:
entrez:
13
12
2022
pubmed:
14
12
2022
medline:
14
12
2022
Statut:
aheadofprint
Résumé
To evaluate the prevalence of ocular surface disease (OSD) signs and symptoms of glaucoma patients in private clinics in relation to topical glaucoma treatment and to compare them to non-glaucomatous population. A multicenter, cross-sectional study consisting of private ophthalmology clinic visits in southern Finland. Glaucoma patients had a diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, or treated ocular hypertension. Control patients had no prior or current use of glaucoma medication. Recorded parameters included OSD signs and symptoms, used glaucoma medications during the past 6 months, and the product name, type, and duration of used antiglaucoma drugs. Glaucoma patients ( Glaucoma patients show higher prevalence of OSD signs and dry eye sensation compared to non-glaucomatous population. The use of preserved glaucoma medication, as well as high number of active compounds and eye drops increase the severity of these parameters. There are significant differences between the types of glaucoma medication used, and therefore the selection of them is important especially in patients suffering from OSD.
Identifiants
pubmed: 36511236
doi: 10.1177/11206721221144339
pmc: PMC9999283
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11206721221144339Références
Clin Ophthalmol. 2020 Jan 14;14:103-111
pubmed: 32021074
Br J Ophthalmol. 2011 Jun;95(6):869-75
pubmed: 21429894
Clin Ophthalmol. 2016 Mar 15;10:445-54
pubmed: 27041987
Acta Ophthalmol. 2020 Aug;98(5):449-454
pubmed: 31885212
Eur J Ophthalmol. 2009 Jul-Aug;19(4):572-9
pubmed: 19551671
Br J Ophthalmol. 2016 Jan;100(1):86-93
pubmed: 26286821
Am J Ophthalmol. 2005 Oct;140(4):598-606
pubmed: 16226511
Ophthalmology. 1999 Mar;106(3):556-63
pubmed: 10080214
Sci Rep. 2019 Mar 12;9(1):4282
pubmed: 30862874
Ophthalmology. 2004 Dec;111(12):2186-92
pubmed: 15582072
Clin Ophthalmol. 2015 May 04;9:785-93
pubmed: 25999687
Arch Ophthalmol. 1994 Nov;112(11):1446-54
pubmed: 7980134
J Glaucoma. 2011 Mar;20(3):172-8
pubmed: 20577105
Ophthalmology. 2013 Nov;120(11):2241-8
pubmed: 23714318
Eur J Ophthalmol. 2017 Nov 8;27(6):694-704
pubmed: 28497458
Health Qual Life Outcomes. 2003 Dec 10;1:75
pubmed: 14667241
Clin Ophthalmol. 2012;6:441-6
pubmed: 22536034
J Glaucoma. 2008 Aug;17(5):350-5
pubmed: 18703943
Br J Ophthalmol. 2012 Jun;96(6):816-20
pubmed: 22493037
J Glaucoma. 2013 Dec;22(9):730-5
pubmed: 23524856
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
pubmed: 17534814
Br J Ophthalmol. 2002 Apr;86(4):418-23
pubmed: 11914211
Curr Eye Res. 2012 Feb;37(2):145-54
pubmed: 22049909